321 related articles for article (PubMed ID: 30726192)
1. Could E-Cadherin and CD10 Expression be Used to Differentiate Between Atypical Endometrial Hyperplasia and Endometrial Carcinoma?
Youssef MY; Mohamed MA
Int J Gynecol Pathol; 2019 Mar; 38(2):128-137. PubMed ID: 30726192
[TBL] [Abstract][Full Text] [Related]
2. E-cadherin and CD10 expression in atypical hyperplastic and malignant endometrial lesions.
Ahmed AR; Muhammad EM
J Egypt Natl Canc Inst; 2014 Dec; 26(4):211-7. PubMed ID: 25282623
[TBL] [Abstract][Full Text] [Related]
3. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma.
McCluggage WG; Oliva E; Herrington CS; McBride H; Young RH
Histopathology; 2003 Aug; 43(2):144-50. PubMed ID: 12877729
[TBL] [Abstract][Full Text] [Related]
4. UbcH10 expression in benign, hyperplastic, and malignant endometrial curetted materials: a tissue microarray study.
Kefeli M; Yildiz L; Celik H; Tosun M; Karagoz F
Int J Surg Pathol; 2012 Aug; 20(4):360-6. PubMed ID: 22415060
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium.
Bircan S; Ensari A; Ozturk S; Erdogan N; Dundar I; Ortac F
Pathol Oncol Res; 2005; 11(1):32-9. PubMed ID: 15800680
[TBL] [Abstract][Full Text] [Related]
6. PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia.
Allison KH; Upson K; Reed SD; Jordan CD; Newton KM; Doherty J; Swisher EM; Garcia RL
Int J Gynecol Pathol; 2012 Mar; 31(2):151-159. PubMed ID: 22317873
[TBL] [Abstract][Full Text] [Related]
7. Role of Morphometry and Matrix Metalloproteinase-9 Expression in Differentiating between Atypical Endometrial Hyperplasia and Low Grade Endometrial Adenocarcinoma.
Assaf MI; Abd El-Aal W; Mohamed SS; Yassen NN; Mohamed EA
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2291-2297. PubMed ID: 30139240
[TBL] [Abstract][Full Text] [Related]
8. CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma.
Omran OM
J Environ Pathol Toxicol Oncol; 2012; 31(3):203-12. PubMed ID: 23339695
[TBL] [Abstract][Full Text] [Related]
9. Expression of Glut-1 in Normal Endometrium and Endometrial Lesions: Analysis of 336 Cases.
Němejcová K; Rosmusová J; Bártů M; Důra M; Tichá I; Dundr P
Int J Surg Pathol; 2017 Aug; 25(5):389-396. PubMed ID: 28381136
[TBL] [Abstract][Full Text] [Related]
10. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease.
Singh M; Spoelstra NS; Jean A; Howe E; Torkko KC; Clark HR; Darling DS; Shroyer KR; Horwitz KB; Broaddus RR; Richer JK
Mod Pathol; 2008 Jul; 21(7):912-23. PubMed ID: 18487993
[TBL] [Abstract][Full Text] [Related]
11. The role of CD10 staining in distinguishing invasive endometrial adenocarcinoma from adenocarcinoma involving adenomyosis.
Nascimento AF; Hirsch MS; Cviko A; Quade BJ; Nucci MR
Mod Pathol; 2003 Jan; 16(1):22-7. PubMed ID: 12527709
[TBL] [Abstract][Full Text] [Related]
12. Heart and Neural Crest Derivatives Expressed Transcript 2 (HAND2): a novel biomarker for the identification of atypical hyperplasia and Type I endometrial carcinoma.
Buell-Gutbrod R; Cavallo A; Lee N; Montag A; Gwin K
Int J Gynecol Pathol; 2015 Jan; 34(1):65-73. PubMed ID: 25473755
[TBL] [Abstract][Full Text] [Related]
13. Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: Correlation with clinicopathologic parameters and biomarkers.
Balmer NN; Richer JK; Spoelstra NS; Torkko KC; Lyle PL; Singh M
Mod Pathol; 2006 Dec; 19(12):1593-605. PubMed ID: 16980945
[TBL] [Abstract][Full Text] [Related]
14. Maspin expression, subcellular localization and clinicopathological correlation in endometrial hyperplasia and endometrial adenocarcinoma.
Blandamura S; Alessandrini L; Saccardi C; Giacomelli L; Fabris A; Borghero A; Litta P
Histol Histopathol; 2014 Jun; 29(6):777-83. PubMed ID: 24346847
[TBL] [Abstract][Full Text] [Related]
15. Expression and clinical significance of ghrelin in endometrial hyperplasia and carcinoma of Egyptian patients.
Younes SF; Aiad H; Kandil M; El Kalashy FS
Ultrastruct Pathol; 2015 May; 39(3):207-13. PubMed ID: 25569277
[TBL] [Abstract][Full Text] [Related]
16. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms.
McCluggage WG; Sumathi VP; Maxwell P
Histopathology; 2001 Sep; 39(3):273-8. PubMed ID: 11532038
[TBL] [Abstract][Full Text] [Related]
17. Utility of Ki-67, p53, Bcl-2, and Cox-2 biomarkers for low-grade endometrial cancer and disordered proliferative/benign hyperplastic endometrium by imprint cytology.
Apostolou G; Apostolou N; Biteli M; Kavantzas N; Patsouris E; Athanassiadou P
Diagn Cytopathol; 2014 Feb; 42(2):134-42. PubMed ID: 23729350
[TBL] [Abstract][Full Text] [Related]
18. Stromal Clues in Endometrial Carcinoma: Loss of Expression of β-Catenin, Epithelial-Mesenchymal Transition Regulators, and Estrogen-Progesterone Receptor.
Senol S; Sayar I; Ceyran AB; Ibiloglu I; Akalin I; Firat U; Kosemetin D; Engin Zerk P; Aydin A
Int J Gynecol Pathol; 2016 May; 35(3):238-48. PubMed ID: 26367784
[TBL] [Abstract][Full Text] [Related]
19. Cervical stromal involvement by endometrial 'hyperplasia': a previously unreported phenomenon with recommendations to report as stage II endometrial carcinoma.
Taylor J; McCluggage WG
Pathology; 2021 Aug; 53(5):568-573. PubMed ID: 34154843
[TBL] [Abstract][Full Text] [Related]
20. Paired boxed gene 1 expression: A single potential biomarker for differentiating endometrial lesions associated with favorable outcomes in patients with endometrial carcinoma.
Liu LC; Lai HC; Chou YC; Huang RL; Yu MH; Lin CP; Tsai WC; Chiang KJ; Wang YC; Chao TK
J Obstet Gynaecol Res; 2016 Sep; 42(9):1159-67. PubMed ID: 27226215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
